June 12 (Reuters) - Cara Therapeutics ( CARA ) said on

Wednesday it will discontinue a mid-to-late stage study for a

neurological condition that causes itching after its oral drug

did not show meaningful clinical benefit versus a placebo.

The company said its experimental oral version of the drug

difelikefalin did not show a meaningful improvement in itching

at any dose.

Notalgia paresthetica is a neurological condition that

causes intense itching, burning or a tingling sensation near the

shoulder blades.